Discontinued — last reported Q1 '25
Roivant Sciences Interest Income decreased by 11.5% to $48.32M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 33.0%, from $72.13M to $48.32M. Over 3 years (FY 2021 to FY 2024), Interest Income shows an upward trend with a 788.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests higher cash reserves or a more favorable interest rate environment, contributing to non-operating profitability.
This represents income earned from cash equivalents, marketable securities, and other interest-bearing financial instrum...
Standard across all industries; high-cash biotechs often show significant interest income due to large capital raises.
other_interest_income_066fec| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $92.25K | $92.25K | $92.25K | $92.25K | $1.98M | $5.67M | $10.25M | $14.28M | $16.72M | $14.30M | $31.95M | $83.46M | $72.13M | $69.77M | $61.85M | $54.62M | $48.32M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | >999% | +186.2% | +80.8% | +39.4% | +17.0% | -14.5% | +123.5% | +161.2% | -13.6% | -3.3% | -11.4% | -11.7% | -11.5% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | +743.8% | +152.2% | +211.8% | +484.3% | +331.5% | +388.0% | +93.6% | -34.5% | -33.0% |